Biotech Deals

Axios Pro: Biotech Deals delivers the latest VC, PE and M&A news across pharma, biotech, health tech and more.

Latest Coverage

Filter by:

All dates

Biotech Deals
16 hours ago
Slate Medicines raises $130M for migraine, headache therapies
Go deeper (1 min. read)
Biotech Deals
Feb 23, 2026
Generate Biomedicines seeks up to $425M in IPO
Go deeper (1 min. read)
Biotech Deals
Feb 23, 2026
Gilead to buy Arcellx for $7.8B
Go deeper (1 min. read)
Biotech Deals
Feb 19, 2026
Crowell & Moring attorney: FDA whiplash fuels biotech uncertainty
Go deeper (1 min. read)
Biotech Deals
Feb 17, 2026
Biopharma VC trends point to continued rebound in 2026
Go deeper (1 min. read)
Biotech Deals
Feb 13, 2026
Exclusive: Alnair Therapeutics seeks $10M seed for Phase 1 cancer drug trial
Go deeper (1 min. read)
Biotech Deals
Feb 11, 2026
Moderna's FDA clash over flu shot deepens vaccine investment jitters
Go deeper (2 min. read)
Biotech Deals
Feb 9, 2026
Eli Lilly to buy Orna Therapeutics in $2.4B deal
Go deeper (1 min. read)

Meet the reporters

Katherine Davis, Biotech Deals Reporter

Katherine Davis is a biotech reporter for Axios Pro Deals. She reports on venture capital, private equity and M&A transactions across the biotech sector.

Biotech Deals

Latest Coverage

Slate Medicines raises $130M for migraine, headache therapies

Generate Biomedicines seeks up to $425M in IPO

Gilead to buy Arcellx for $7.8B

Crowell & Moring attorney: FDA whiplash fuels biotech uncertainty

Biopharma VC trends point to continued rebound in 2026

Exclusive: Alnair Therapeutics seeks $10M seed for Phase 1 cancer drug trial

Moderna's FDA clash over flu shot deepens vaccine investment jitters

Eli Lilly to buy Orna Therapeutics in $2.4B deal

Meet the reporters